Beam Therapeutics Inc

BEAM is exhibiting a Stage 3 distribution phase, marked by a Support Failure breakdown through key horizontal support on elevated volume. Medium-term bias remains bearish, permitting sell-side engagement, while price is extended below declining EMAs and extreme oversold readings caution against immediate selling. Execution is best deferred, stalking for a pullback into the 9/20/50 EMA and prior support zone to sell into stalled rallies. The long-term uptrend remains intact, tempering aggressive downside expectations.

• ↑Beam 101 Phase 1 trial reports marked HbS induction and total hemoglobin gain.
• ↑Ends Q2 with $1.15B cash, extending funding runway into mid-2029.
• ↓EPS forecast cut to $1.25 loss as development costs rise.